Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Jun 13, 2023 (3 years ago)

Tranexamic Acid USP Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Tranexamic Acid USP Tablets, 650 mg, 30 tablets (3X10) Unit Dose, Rx Only, Manufactured for: AvKARE Pulaski, TN 38478, NDC 50268-772-13

Affected NDC 50268-0772-13

Compare with the code on your package — it is the most precise check available.

Drug: Tranexamic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Tranexamic Acid
NDC 50268-0772
650 mg/1 Tablet
Oral
AvPAK Rx
Recalling firm
Avkare LLC
NDC code
50268-772-13
Origin
TN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0875-2023 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Tranexamic recalls

See all
Class III · Low risk

Lysteda (tranexamic acid)

Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

Terminated Impurity / degradation Amring Pharmaceuticals Inc NDC 69918-301-30 D-0871-2023
Class I · High risk

Tranexamic Acid Injection

Labeling: Label Mix-Up; potential for cartons labeled as Tranexamic Acid Injection, USP to contain vials of Amiodarone HCl Injection, USP and cartons labeled as Amiodarone HCl Injection, USP to contain vials of Tranexamic Acid Injection, USP.

Terminated Labeling / mix-up Mylan Institutional LLC NDC 67457-197-00 D-1576-2020
Class II · Moderate risk

Tranexamic Acid active pharmaceutical ingredient packaged in…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-938-2015

Other recalls by Avkare LLC

All 2023 recalls
Class II · Moderate risk

Amantadine HCl

Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.

Ongoing Dissolution failure AvKARE NDC 50268-069-15 D-0341-2026